Skip to main content
. 2021 Nov 22;2021:6642171. doi: 10.1155/2021/6642171

Figure 4.

Figure 4

(a) Expression of PI3K/AKT/mTOR-related proteins examined using western blots after treatment with/without SQYZD (0, 2, 4, and 8 mg/ml). (b) Expression of PI3K/AKT/mTOR-related proteins examined using western blots after treatment with 5 μM IGF, an agonist to PI3K/AKT/mTOR signaling pathway, or along with 4 mg/ml SQYZD. (c) Simple mode diagram of SQYZD acting on the PI3K/AKT/mTOR signaling pathway.